Drug therapy for hyperthyroidism in pregnancy: safety issues for mother and fetus
- PMID: 11005705
- DOI: 10.2165/00002018-200023030-00005
Drug therapy for hyperthyroidism in pregnancy: safety issues for mother and fetus
Abstract
Hyperthyroidism (thyrotoxicosis) in pregnancy and the child bearing years is usually attributable to Graves' disease. This is an autoimmune condition in which thyroid-stimulating immunoglobulins (TSI) cause hyperthyroidism. As a rule, pregnancy complicates the management of hyperthyroidism, rather than vice versa. However, patients who remain thyrotoxic during pregnancy are at increased risk of maternal and fetal complications, particularly miscarriage and stillbirth. Therefore, bodyweight loss, eye signs and a bruit over the thyroid gland in a pregnant woman warrant thyroid investigation. Investigations should include measurement of serum free thyroid hormone levels [free thyroxine (T4) and free triiodothyronine (T3)] rather than total T4 and T3 levels, because total T4 and T3 levels may be raised in euthyroid pregnancies due to the presence of increased levels of thyroxine binding globulin (TBG). By 20 weeks' gestational age, the fetal thyroid is fully responsive to TSI and to antithyroid drugs. Maternal T4 and T3 and thyrotropin pass across the placenta in small and decreasing amounts as gestation progresses, but thyrotropin releasing hormone, TSI, antithyroid drugs, iodides and beta-blockers are readily transferred to the fetus from the mother. Hyperthyroidism is usually treated throughout pregnancy with an antithyroid drug, preferably propylthiouracil. The smallest dose which controls the disease is given with careful monitoring of free T4 and T3 levels to minimise the risk of fetal hypothyroidism and goitre. Bilateral subtotal thyroidectomy may be an option for a small number of patients with hyperthyroidism in pregnancy.
Similar articles
-
Management of Graves' hyperthyroidism in pregnancy: focus on both maternal and foetal thyroid function, and caution against surgical thyroidectomy in pregnancy.Eur J Endocrinol. 2009 Jan;160(1):1-8. doi: 10.1530/EJE-08-0663. Epub 2008 Oct 10. Eur J Endocrinol. 2009. PMID: 18849306 Review.
-
Pharmacokinetics and pharmacotherapy of thionamides in pregnancy.Ther Drug Monit. 2006 Aug;28(4):477-83. doi: 10.1097/00007691-200608000-00001. Ther Drug Monit. 2006. PMID: 16885714 Review.
-
[Pregnancy (conception) in hyper- or hypothyroidism].Ned Tijdschr Geneeskd. 2001 Apr 14;145(15):727-31. Ned Tijdschr Geneeskd. 2001. PMID: 11332254 Review. Dutch.
-
Fetal cord blood sampling in the diagnosis and the treatment of fetal hyperthyroidism in the offsprings of a euthyroid mother, producing thyroid stimulating immunoglobulins.Ann Endocrinol (Paris). 1997;58(4):338-42. Ann Endocrinol (Paris). 1997. PMID: 9436485
-
[Severe neonatal hyperthyroidism which reveals a maternal Graves' disease].Ann Endocrinol (Paris). 2004 Apr;65(2):125-30. doi: 10.1016/s0003-4266(04)95660-0. Ann Endocrinol (Paris). 2004. PMID: 15247872 French.
Cited by
-
Maternal Thyroid Anomalies and Attention-Deficit Hyperactivity Disorder in Progeny.Am J Epidemiol. 2022 Feb 19;191(3):430-440. doi: 10.1093/aje/kwab272. Am J Epidemiol. 2022. PMID: 34791037 Free PMC article.
-
Graves disease in childhood: a review of the options for diagnosis and treatment.Paediatr Drugs. 2003;5(2):95-102. doi: 10.2165/00128072-200305020-00003. Paediatr Drugs. 2003. PMID: 12529162 Review.
-
The Tired Pregnant Woman.Clin Pract Cases Emerg Med. 2021 Nov;5(4):494-498. doi: 10.5811/cpcem.2021.5.51401. Clin Pract Cases Emerg Med. 2021. PMID: 34813456 Free PMC article.
-
Maternal hyperthyroidism increases the prevalence of foregut atresias in fetal rats exposed to adriamycin.Pediatr Surg Int. 2014 Feb;30(2):151-7. doi: 10.1007/s00383-013-3445-y. Pediatr Surg Int. 2014. PMID: 24363086
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous